In December 2017, the US Food & Drug Administration (FDA) approved Luxturna from Spark Therapeutics — the first gene therapy to win market approval in the US. Several other gene therapy programs ...

The first NHS patients have started treatment with Novartis’ Luxturna, a gene therapy for a sight-robbing inherited disease, after the drugmaker agreed a discount on its £613,000 list price ...

Last month an FDA advisory committee voted unanimously in favour of approval for voretigene neparvovec (to be named Luxturna) for patients with confirmed biallelic RPE-mediated inherited retinal ...